Mesoblast Ltd (MESO) stock

MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 27, 2026Score 6/30

$13.27+0.17 (+1.30%)

Close on Nov 13, 2026Market cap $1.72BP/E –Yield –

Earnings

Mesoblast's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report

–

Not yet scheduled

Revenue, Q2 FY2026

$51.30M

EPS, Q2 FY2026

-$3.11

Latest guidance

Issued

Feb 27, 2026 · 1 item

Quarterly results

Revenue and earnings per share from each of Mesoblast's earnings releases, newest first

Quarter	Reported	Revenue	YoY	EPS	Source
Q4 FY2026ended Jun 30, 2026	Aug 27, 2026before the open	–	–	–	Release
Q2 FY2026ended Dec 31, 2025	Feb 27, 2026before the open	$51.30M	–	-$3.11	Release
Q4 FY2025ended Jun 30, 2025	Aug 29, 2025before the open	–	–	–	Release
Q2 FY2025ended Dec 31, 2024	Feb 28, 2025after the close	–	–	–	Release
Q4 FY2024ended Jun 30, 2024	Aug 29, 2024before the open	–	–	–	Release
Q2 FY2024ended Dec 31, 2023	Mar 1, 2024after the close	–	–	–	Release
Q4 FY2023ended Jun 30, 2023	Aug 31, 2023before the open	–	–	–	Release
Q3 FY2023ended Mar 31, 2023	May 26, 2023before the open	$1.94M	–	-$2.53	Release
Q2 FY2023ended Dec 31, 2022	Feb 28, 2023after the close	–	–	–	Release
Q1 FY2023ended Sep 30, 2022	Nov 28, 2022before the open	–	–	–	Release
Q4 FY2022ended Jun 30, 2022	Aug 31, 2022before the open	–	–	–	Release
Q3 FY2022ended Mar 31, 2022	Jun 3, 2022before the open	–	–	–	Release
Q2 FY2022ended Dec 31, 2021	Feb 28, 2022after the close	–	–	–	Release
Q1 FY2022ended Sep 30, 2021	Nov 26, 2021after the close	–	–	–	Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Mesoblast's latest outlook for periods it has not reported yet, compared with what it said before

Metric	Period	Guidance	Before	Change	Given
Ryoncil® net revenue	FY2026	$110.00M – $120.00M	–	New	Feb 27, 2026

Guidance history

Every forecast Mesoblast put in an earnings release, newest first

Given	Metric	Period	Guidance	Change
Feb 27, 2026	Ryoncil® net revenue	FY2026	$110.00M – $120.00M	New

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.